DigestRedComo funciona
Red
/
Empresas
No
No verificado

Novartis Pharma AG

Sobre qué escribimos

Anuncios brevesFarmacéuticaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

111 Comunicados de prensa

Ver todos los comunicados de prensa
31/07/2026
Farmacéutica
Anuncios breves
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
20/07/2026
Farmacéutica
Gestión empresarial/Administración de Empresas
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
16/07/2026
Farmacéutica
Anuncios breves
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
05/07/2026
Farmacéutica
Anuncios breves
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
01/07/2026
Farmacéutica
Anuncios breves
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
12/06/2026
Farmacéutica
Medicina Salud Bienestar
Anuncios breves
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
10/06/2026
Farmacéutica
Anuncios breves
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
08/06/2026
Farmacéutica
Anuncios breves
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
04/06/2026
Farmacéutica
Anuncios breves
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
03/06/2026
Farmacéutica
Anuncios breves
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0